Table 4 Mean change from baseline in BCVA at 6 months

IVR 0.5 mg vs non-anti-VEGF

Type of RVO

  All trials

4

12.30 (10.03,14.58)

<0.001

1.66

0.646

0.00%

  CRVO

2

14.05 (10.54, 17.56)

<0.001

0.02

0.900

0.00%

  BRVO

2

11.05 (8.07, 14.02)

<0.001

0.01

0.933

0.00%

Sample size

  All trials

4

12.30 (10.03,14.58)

<0.001

1.66

0.646

0.00%

  >100

2

12.43 (9.40, 15.46)

<0.001

1.61

0.205

37.9%

  <100

2

11.74 (3.98, 19.51)

<0.001

0.03

0.868

0.00%

Different non-anti-VEGF treatment

  All trials

4

12.30 (10.03,14.58)

<0.001

1.66

0.646

0.00%

  Sham

3

12.37 (10.02, 14.72)

<0.001

1.62

0.446

0.00%

  Sham plus laser

1

11.40 (2.64, 20.16)

0.011

-

IVR 0.5 mg vs IVR 0.3 mg

2

1.90 (−0.35, 4.16)

0.098

0.05

0.831

0.00%

IVR 0.3 mg vs non-anti-VEGF

2

10.26 (7.80, 12.72)

<0.001

1.11

0.293

9.50%